At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
Softgel containing placebo +1 moredietary
Likely dose
Softgel containing 250mg of Urolithin A (Mitopure)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of Urolithin A Supplementation on Mitochondrial Health of Immune Cells (MitoImmune): a Randomized Trial
In Brief
A clinical study evaluating Softgel containing placebo and Softgel containing 250mg of Urolithin A (Mitopure) for Aging. Completed, enrolled 50 participants across 1 site.
Detailed Summary
To show that a natural mitophagy activator (Urolithin A) given orally can modulate mitochondrial activity in immune cells in healthy adults and this results in better immune function
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAging
CountriesGermany
CollaboratorsGoethe University
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartJan 2023
First PostedFeb 2023
Primary CompletionMar 2024
Study CompletionAug 2024
TodayJul 2026
First PostedFeb 21, 2023
Enrollment StartJan 30, 2023
Primary CompletionMar 31, 2024
Study CompletionAug 31, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 3.4 years ago
Interventions
Softgel containing placebodietary
Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
Softgel containing 250mg of Urolithin A (Mitopure)dietary
Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days